The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor: A Randomized Trial
Abstract
CONTEXT: Adjuvant imatinib administered for 12 months after surgery has improved recurrence-free survival (RFS) of patients with operable gastrointestinal stromal tumor (GIST) compared with placebo. OBJECTIVE: To investigate the role of imatinib administration duration as adjuvant treatment of patients who have a high estimated risk for GIST recurrence after surgery. DESIGN, SETTING, AND PATIENTS: Patients with KIT-positive GIST removed at surgery were entered between February 2004 and September 2008 to this randomized, open-label phase 3 study conducted in 24 hospitals in Finland, Germany, Norway, and Sweden. The risk of GIST recurrence was estimated using the modified National Institutes of Health Consensus Criteria. INTERVENTION: Imatinib, 400 mg per day, orally for either 12 months or 36 months, started within 12 weeks of surgery. MAIN OUTCOME MEASURES: The primary end point was RFS; the secondary end points included overall survival and treatment safety. RESULTS: Two hundred patients were allocated to each group. The median follow-up time after randomization was 54 months in December 2010. Diagnosis of GIST was confirmed in 382 of 397 patients (96%) in the intention-to-treat population at a central pathology review. KIT or PDGFRA mutation was detected in 333 of 366 tumors (91%) available for testing. Patients assigned for 36 months of imatinib had longer RFS compared with those assigned for 12 months (hazard ratio [HR], 0.46; 95% CI, 0.32-0.65; P < .001; 5-year RFS, 65.6% vs 47.9%, respectively) and longer overall survival (HR, 0.45; 95% CI, 0.22-0.89; P = .02; 5-year survival, 92.0% vs 81.7%). Imatinib was generally well tolerated, but 12.6% and 25.8% of patients assigned to the 12- and 36-month groups, respectively, discontinued imatinib for a reason other than GIST recurrence. CONCLUSION: Compared with 12 months of adjuvant imatinib, 36 months of imatinib improved RFS and overall survival of GIST patients with a high risk of GIST recurrence. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00116935.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Diagnosis of gastrointestinal stromal tumors: A consensus approach
Fletcher, C. D. M., Berman, J. J., Corless, C., Gorstein, F., Lasota, J., Longley, B. J., Miettinen, M., O'Leary, T. J., Remotti, H., Rubin, B. P., et al. (2002) · Human Pathology · doi:10.1053/hupa.2002.123545 · Cited by 3,419
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
Heinrich, M. C., Corless, C. L., Demetri, G. D., Blanke, C. D., von Mehren, M., Joensuu, H., McGreevey, L. S., Chen, C.-J., Van den Abbeele, A. D., Druker, B. J., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.190 · Cited by 2,299
Self-citationGastrointestinal stromal tumors: Pathology and prognosis at different sites
Miettinen, M., & Lasota, J. (2006) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2006.09.001 · Cited by 2,052
Verweij, J., Casali, P. G., Zalcberg, J., LeCesne, A., Reichardt, P., Blay, J.-Y., Issels, R., van Oosterom, A., Hogendoorn, P. C., Van Glabbeke, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17098-0 · Cited by 1,665
Self-citationDeMatteo, R. P., Ballman, K. V., Antonescu, C. R., Maki, R. G., Pisters, P. W., Demetri, G. D., Blackstein, M. E., Blanke, C. D., von Mehren, M., Brennan, M. F., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60500-6 · Cited by 1,369
Nilsson, B., Bümming, P., Meis‐Kindblom, J. M., Odén, A., Dortok, A., Gustavsson, B., Sablinska, K., & Kindblom, L. (2005) · Cancer · doi:10.1002/cncr.20862 · Cited by 1,272
Self-citationRisk stratification of patients diagnosed with gastrointestinal stromal tumor
Joensuu, H. (2008) · Human Pathology · doi:10.1016/j.humpath.2008.06.025 · Cited by 1,235
Self-citationCardiotoxicity of the cancer therapeutic agent imatinib mesylate
Kerkelä, R., Grazette, L., Yacobi, R., Iliescu, C., Patten, R., Beahm, C., Walters, B., Shevtsov, S., Pesant, S., Clubb, F. J., et al. (2006) · Nature Medicine · doi:10.1038/nm1446 · Cited by 1,159
Gastrointestinal stromal tumour
Rubin, B. P., Heinrich, M. C., & Corless, C. L. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60780-6 · Cited by 1,036
Joensuu, H., Vehtari, A., Riihimäki, J., Nishida, T., Steigen, S. E., Brabec, P., Plank, L., Nilsson, B., Cirilli, C., Braconi, C., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70299-6 · Cited by 997
Self-citationBlanke, C. D., Demetri, G. D., von Mehren, M., Heinrich, M. C., Eisenberg, B., Fletcher, J. A., Corless, C. L., Fletcher, C. D. M., Roberts, P. J., Heinz, D., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.4403 · Cited by 996
Self-citationDebiec-Rychter, M., Sciot, R., Le Cesne, A., Schlemmer, M., Hohenberger, P., van Oosterom, A. T., Blay, J.-Y., Leyvraz, S., Stul, M., Casali, P. G., et al. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.01.030 · Cited by 892
Self-citationGold, J. S., Gönen, M., Gutiérrez, A., Broto, J. M., García-del-Muro, X., Smyrk, T. C., Maki, R. G., Singer, S., Brennan, M. F., Antonescu, C. R., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70242-6 · Cited by 507
DeMatteo, R. P., Gold, J. S., Saran, L., Gönen, M., Liau, K. H., Maki, R. G., Singer, S., Besmer, P., Brennan, M. F., & Antonescu, C. R. (2008) · Cancer · doi:10.1002/cncr.23199 · Cited by 503
Blay, J.-Y., Le Cesne, A., Ray-Coquard, I., Bui, B., Duffaud, F., Delbaldo, C., Adenis, A., Viens, P., Rios, M., Bompas, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.0183 · Cited by 392
Wardelmann, E., Merkelbach-Bruse, S., Pauls, K., Thomas, N., Schildhaus, H.-U., Heinicke, T., Speidel, N., Pietsch, T., Buettner, R., Pink, D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1211 · Cited by 365
Self-citationRutkowski, P., Nowecki, Z. I., Michej, W., Dębiec-Rychter, M., Woźniak, A., Limon, J., Siedlecki, J., Grzesiakowska, U., Kąkol, M., Osuch, C., et al. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9377-9 · Cited by 263
Gastrointestinal Stromal Tumors With KIT Exon 11 Deletions Are Associated With Poor Prognosis
Andersson, J., Bümming, P., Meis–Kindblom, J. M., Sihto, H., Nupponen, N., Joensuu, H., Odén, A., Gustavsson, B., Kindblom, L., & Nilsson, B. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.01.043 · Cited by 237
Self-citationAn Evaluation of 2537 Gastrointestinal Stromal Tumors for a Proposed Clinical Staging System
Woodall, C. E. (2009) · Archives of Surgery · doi:10.1001/archsurg.2009.108 · Cited by 112
Takahashi, T., Nakajima, K., Nishitani, A., Souma, Y., Hirota, S., Sawa, Y., & Nishida, T. (2007) · International Journal of Clinical Oncology · doi:10.1007/s10147-007-0705-7 · Cited by 101
Trent, J. C., Patel, S. S., Zhang, J., Araujo, D. M., Plana, J., Lenihan, D. J., Fan, D., PATEL, S. R., Benjamin, R. S., & Khakoo, A. Y. (2009) · Cancer · doi:10.1002/cncr.24683 · Cited by 77
Cited by
Demetri, G. D., Reichardt, P., Kang, Y.-K., Blay, J.-Y., Rutkowski, P., Gelderblom, H., Hohenberger, P., Leahy, M., von Mehren, M., Joensuu, H., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61857-1 · Cited by 1,406
Self-citationCherny, N. I., Sullivan, R., Dafni, U., Kerst, J. M., Sobrero, A., Zielinski, C., de Vries, E. G. E., & Piccart, M. J. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv249 · Cited by 818
Gastrointestinal stromal tumour
Joensuu, H., Hohenberger, P., & Corless, C. L. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60106-3 · Cited by 703
Self-citationNishida, T., Blay, J.-Y., Hirota, S., Kitagawa, Y., & Kang, Y.-K. (2016) · Gastric Cancer · doi:10.1007/s10120-015-0526-8 · Cited by 486
Imatinib: A Breakthrough of Targeted Therapy in Cancer
Iqbal, N., & Iqbal, N. (2014) · Chemotherapy Research and Practice · doi:10.1155/2014/357027 · Cited by 470
Metadata
- Authors
- Joensuu, H., Eriksson, M., Sundby Hall, K., Hartmann, J. T., Pink, D., Schütte, J., Ramadori, G., Hohenberger, P., Duyster, J., Al-Batran, S.-E., Schlemmer, M., Bauer, S., Wardelmann, E., Sarlomo-Rikala, M., Nilsson, B., Sihto, H., Monge, O. R., Bono, P., Kallio, R., Vehtari, A., Leinonen, M., Alvegård, T., & Reichardt, P.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2012-03-28
- Volume
- 307
- Issue
- 12
- Pages
- 1265
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W1970687736
- Cited by
- 980
- References
- 22
- FWCI
- 93.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.